Q&A Zealand Pharma 2019-12-03
Aktiesnakken
NOVO
Genmab
Bavarian Nordic
Shipping
Grønne Aktier
Medico
TESLA
Biotek-snakken
Zealand Pharma
Amerikanske aktier
ExpreS2ion
Chemometec
Gubra
Laks
Pharma
Banker og Finans
AMBU
BITCOIN
GN Store Nord
EL-BILER
AI/Kunstig intelligens
Hansa Biopharma
OLIE OG GAS
Krypto
Vestas
3/12 18:03 af collersteen |
What has surprised you the most (positively and negatively) compared to your expectations before you took over as CEO?
| |
3/12 18:05 af Emmanuel Dulac |
I am most positively surprised by the quality of Zealand's leadership team, and the highly collaborative culture of the employees. The more I work with the research team, the more I am impressed by their expertise...
| |
3/12 18:08 af Emmanuel Dulac |
As for negatives (if it can be called that), there remains a lot of education around what the artificial pancreas can mean for people with insulin-dependent diabetes.
| |
3/12 18:09 af Stroka |
Do you expect Zealand Pharma to be an independent company in 2025?
| |
3/12 18:10 af Emmanuel Dulac |
Zealand is undergoing transformation to support sales of its own products, and we are planning to launch four products in four years starting in 2021. We have ambitious plans, industry leading competencies, and a strong financial position to realize our strategy.
| |
3/12 18:10 af Helge Larsen/PI-redaktør |
Emmanuel Dulac..Thank You for joining us and thank you for the many fullfillinganswers to our questions. We look forward to to seeing you back here onProInvestor.com after Q4.
| |
3/12 18:11 af Emmanuel Dulac |
Thank you! Thank you for the thoughtful questions. Always a pleasure to discuss with all of you.
| |
3/12 18:11 af Helge Larsen/PI-redaktør |
This session has ended.
|